Скачать или смотреть The viability of CSF biomarkers in patients with brain tumors

Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, discusses the current state of cerebrospinal fluid (CSF) biomarkers for patients with brain tumors. Important considerations include anatomical location, tumor to CSF contact, and blood-brain barrier disruption in evaluating biomarkers such as 2-hydroxyglutarate and cell-free DNA (cfDNA). Whilst CSF as a liquid biopsy source has potential, clinicians need to address challenges such as distinguishing progression from radiation necrosis in patients with glioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.